Back to top

Image: Bigstock

Zacks Investment Ideas feature highlights: Apple, Eli Lilly and Crocs

Read MoreHide Full Article

For Immediate Release

Chicago, IL – May 17, 2024 – Today, Zacks Investment Ideas feature highlights Apple (AAPL - Free Report) , Eli Lilly (LLY - Free Report) and Crocs (CROX - Free Report) .

3 Stocks to Buy Following Positive Earnings Results

Earnings season continues to wind down, with the period reflecting positivity. We’ve heard from over 460 S&P 500 companies, with this week’s reporting docket primarily dominated by retail.

Total earnings for the S&P 500 members that have reported Q1 results are up +4.8% from the same period last year on +4.1% higher revenues. The earnings growth pace reflects an acceleration relative to other periods, undoubtedly a positive development.

Estimates for the coming 2024 Q2 cycle have been trending higher, reflecting optimism among analysts.

So far, several companies, including Apple, Eli Lilly and Crocs, have seen post-earnings positivity. Let’s take a closer look at each.


Concerning headline figures, the company posted a 1.3% beat relative to the Zacks Consensus EPS estimate and posted sales 1% ahead of expectations. It reflected the company’s fifth consecutive double-beat, owing to its ability to positively surprise investors.

Notably, the tech titan announced the biggest buyback in corporate history totaling $110 billion. Reflecting further positivity, Apple also unveiled a 4% boost to its quarterly payout, reflecting the 12th consecutive year of higher payouts.

Earnings expectations have increased since the release, reflecting analysts’ optimistic view.

The company’s growth profile remains positive, with current expectations alluding to a 7% pop in earnings on modestly higher sales in its current fiscal year (FY24). Peeking ahead to FY25, estimates allude to an additional 9.6% climb in earnings paired with a 5.5% sales bump.

Eli Lilly

Eli Lilly posted EPS of $2.58 and sales of $8.8 billion, reflecting growth rates of 46% and 26%, respectively. Revenue growth was driven by strong demand, causing LLY to up its full-year revenue guidance by $2 billion.

The revisions trend for its current fiscal year has been notably bullish, up 10% over the last year to $13.37 per share and suggesting 110% year-over-year growth. Sales growth is forecasted to be robust as well, with the current $43 billion estimate 26% higher than FY23.

Sales growth is forecasted to be robust as well, with the current $43 billion estimate 26% higher than FY23.

It’s worth noting that the company has increasingly rewarded its shareholders over the years, boasting a 15% five-year annualized dividend growth rate.


Crocs continued its earnings positivity, posting a 34% beat relative to the Zacks Consensus EPS estimate and reporting sales 6% ahead of expectations. Impressively, the company has exceeded our consensus EPS estimate by an average of 17% across its last four quarterly releases.

Q1 revenue of $939 million grew 6% year-over-year, also reflecting a quarterly record. The company raised its adjusted EPS guidance following the favorable quarter, further showing positivity.

CROX shares have been notably strong in 2024, gaining 50% compared to the S&P500’s 12% gain. The stock is a Zacks Rank #2 (Buy).

Bottom Line

Overall, the 2024 Q1 earnings season has reflected positivity, underpinned by the technology sector’s strong growth.

And concerning positive surprises, all three stocks above delivered just that, also enjoying post-earnings buying pressure.

Why Haven’t You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

Apple Inc. (AAPL) - free report >>

Eli Lilly and Company (LLY) - free report >>

Crocs, Inc. (CROX) - free report >>

Published in